Table 3.

Univariable and multivariable analysis for overall survival in patients with mHSPC treated with ADT

					Multivariable
		Univariable			Model I (Base line PSA adjusted) (n = 52; chi-square 26.5; AIC 122.9)			Model II (n = 52; chi-square 22.8; AIC 121.1)
Factors	Group	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Age	Continuous	1.01	0.96–1.07	0.702
ECOG-PS	1 vs 0	1.10	0.26–4.76	0.895
Log-transformed baseline PSA level (ng/dL)	Continuous	0.81	0.67–0.99	0.035	1.25	0.58–2.71	0.572
Baseline Hb level(g/dl)	Low vs normal	1.90	0.85–4.27	0.120
Baseline ALP level (IU/l)	High vs normal	1.34	0.60–3.02	0.480
Baseline LDH level (IU/l)	High vs normal	1.08	0.48–2.43	0.846
Presence of bone pain	Yes vs No	2.23	1.00–4.98	0.049
Biopsy Gleason score	≥8 vs ≤7	0.55	0.16–1.89	0.345
Visceral metastasis	Yes vs No	5.37	1.18–24.32	0.029
EOD score	≥3 vs ≤2	3.85	1.55–9.59	0.004	1.97	0.61–6.39	0.256	2.05	0.65–6.46	0.222
Sub-group in the CHAARTED trial	high vs low	2.03	0.86–4.82	0.109
Log-transformed PSA change (baseline-12wks)	Continuous	0.78	0.64–0.95	0.014	0.55	0.26–1.18	0.123	0.68	0.54–0.85	0.001
Hb level at 12 weeks	Low vs normal	2.44	1.12–5.31	0.025	2.54	0.92–7.00	0.071	2.58	0.95–7.04	0.060
ALP level at 12 weeks	High vs normal	3.47	1.59–7.58	0.002	3.37	1.01–11.23	0.048	3.57	1.11–11.53	0.030
LDH level at 12 weeks	High vs normal	1.74	0.75–4.00	0.197

mHSPC metastatic hormone-sensitive prostate cancer, ADT androgen deprivation therapy, ECOG Eastern Cooperative Oncology Group, PSA prostate specific antigen, Hb hemoglobin, ALP Alkaline phosphatase, LDH Lactate dehydrogenase, EOD extend of bone metastasis, HR hazard ratio, CI confidence interba